Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADX-038 in Geographic Atrophy Secondary to AMD
NCT06990269Phase 2Recruiting
- Sponsor
- ADARx Pharmaceuticals
- Start
- Nov 2025
- Primary completion
- Feb 2030
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 12
01
Overview
A Phase 2 trial of agazisiran in geographic atrophy (GA), sponsored by ADARx Pharmaceuticals. Started Nov 2025; status: recruiting.
02
Drugs
agazisiran
03
Conditions
geographic atrophy (GA)
Beyond the preview
Go deeper on NCT06990269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06990269.